All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Prognosis of Good syndrome: mortality and morbidity of thymoma associated immunodeficiency in perspective

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F16%3A00065741" target="_blank" >RIV/00159816:_____/16:00065741 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216224:14110/16:00090643

  • Result on the web

    <a href="http://www.sciencedirect.com/science/article/pii/S1521661616302509" target="_blank" >http://www.sciencedirect.com/science/article/pii/S1521661616302509</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1016/j.clim.2016.07.025" target="_blank" >10.1016/j.clim.2016.07.025</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Prognosis of Good syndrome: mortality and morbidity of thymoma associated immunodeficiency in perspective

  • Original language description

    Good syndrome (GS) or thymoma-associated immunodeficiency, is a rare condition that has only been studied in retrospective case series. General consensus was that GS has a worse prognosis than other humoral immunodeficiencies. In this study, physicians of GS patients completed two questionnaires with a two year interval with data on 47 patients, 499 patient years in total. Results on epidemiology, disease characteristics, and outcome are presented. Mean age at diagnosis was 60 years and median follow-up from onset of symptoms was 9 years. There was a high frequency of respiratory tract infections due to encapsulated bacteria. Median survival was 14 years. Survival was reduced compared to age-matched population controls (5-year survival: 82% versus 95%, p = 0.008). In this cohort survival was not associated with gender (HR 0.9, 95% CI 0.3-3.0), autoimmune diseases (HR 2.9, 95% CI 0.8-10.1) or immunosuppressive use (HR 0.3, 95% CI: 0.1-1.2). (C) 2016 The Authors. Published by Elsevier Inc.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FN - Epidemiology, infection diseases and clinical immunology

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2016

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Clinical Immunology

  • ISSN

    1521-6616

  • e-ISSN

  • Volume of the periodical

    171

  • Issue of the periodical within the volume

    October

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    6

  • Pages from-to

    12-17

  • UT code for WoS article

    000386195100002

  • EID of the result in the Scopus database